The Effects and Safety of High Dose Vitamin D3 in Hemodialysis Patients

Main Article Content

Adnane Guella https://orcid.org/0000-0002-4026-4268
Abduelmula R Abduelkarem https://orcid.org/0000-0003-4481-7779
Mohammed Hassanein https://orcid.org/0000-0002-3540-0595

Keywords

Hemodialysis, Secondary hyperparathyroidism, Hypercalcemia, Vitamin D3, Parathyroid hormone

Abstract

Background: Different studies have shown that hemodialysis patients require higher doses of Vitamin D3 (VD3) than the general population to achieve satisfactory replenishment. This study aims to assess the safety of such practice and its benefits on some of the parameters of Chronic Kidney Disease- Mineral and Bone Disorder (CKD-MBD). Methods: A single-center clinical trial assessing the benefits of high dose VD3 in hemodialysis patients. The dose of VD3 (300,000 IU) was administered orally and monthly from April to December 2020 (9 months) at the dialysis unit. The data analyzed were blood levels of calcium, phosphorus, alkaline phosphatase, 25(OH)D, 1,25(OH)2D and intact parathyroid hormone (iPTH) done every three months. Results: We could recruit a cohort of 23 patients. Blood levels of 25(OH)D increased significantly in 82.6% of the patients to above 30 ng/ml. A similar effect was observed with 1, 25(OH)2D levels. iPTH levels decreased significantly when levels of 25(OH)D exceeded 30ng/ml at the end of the nine months. Vitamin D serum levels were typically measured immediately before the next monthly dose was administered. Blood levels of calcium, phosphorus, and alkaline phosphatase were stable during the study period. No events of hypercalcemia were reported, and no patient discontinued the monthly VD3 supplementation. Conclusion: Monthly administration of a high dose of VD3 over a long period of nine months in hemodialysis patients was found to be safe and beneficial in VD3 replenishment. It also allowed a significant decrease in iPTH levels. Further studies are warranted to identify the therapeutic target level of 25(OH)D in hemodialysis patients, allowing beneficial effects on iPTH.

Abstract 965 | PDF Downloads 865

References

1. Del Valle E, Negri AL, Aguirre C, et al. Prevalence of 25(OH) vitamin D insufficiency and deficiency in chronic kidney disease stage 5 patients on hemodialysis. Hemodial Int. 2007;11(3):315-21. http://dx.doi.org/10.1111/j.1542-4758.2007.00186.x
2. Ravani P, Malberti F, Tripepi G, et al. Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int. 2009;75(1):88- 95. http://dx.doi.org/10.1038/ki.2008.501
3. Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int. 2007;71(1):31-8. http://dx.doi.
org/10.1038/sj.ki.5002009
4. Kim SM, Choi HJ, Lee JP, et al. Prevalence of vitamin D deficiency and effects of supplementation with cholecalciferol in patients with chronic kidney disease. J Ren Nutr. 2014;24(1):20-5. http://dx.doi.org/10.1053/j.jrn.2013.07.003
5. Wolf M, Shah A, Gutierrez O, et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int. 2007;72(8):1004-13. http://dx.doi.org/10.1038/sj.ki.5002451
6. Barreto DV, Barreto FC, Liabeuf S, et al. Vitamin D affects survival independently of vascular calcification in chronic kidney disease. Clin J Am Soc Nephrol. 2009;4(6):1128-35. http://dx.doi.org/10.2215/cjn.00260109
7. Lu RJ, Zhu SM, Tang FL, et al. Effects of vitamin D or its analogues on the mortality of patients with chronic kidney disease: an updated systematic review and meta-analysis. Eur J Clin Nutr. 2017;71(6):683-93. http://dx.doi.org/10.1038/ejcn.2017.59
8. Mann MC, Hobbs AJ, Hemmelgarn BR, et al. Effect of oral vitamin D analogs on mortality and cardiovascular outcomes among adults with chronic kidney disease: a meta-analysis. Clin Kidney J. 2015;8(1):41-8. http://dx.doi.org/10.1093/ckj/sfu122
9. Zheng Z, Shi H, Jia J, et al. Vitamin D supplementation and mortality risk in chronic kidney disease: a meta-analysis of 20 observational studies. BMC Nephrol. 2013;14(1):199. http://dx.doi.org/10.1186/1471-2369-14-19
10. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266-81. http://dx.doi.org/10.1056/NEJMra07055 
11. Wasse H, Huang R, Long Q, et al. Efficacy and safety of a short course of very-high-dose cholecalciferol in hemodialysis. Am J Clin Nutr. 2012;95(2):522-8. http://dx.doi.org/10.3945/ajcn.111.025502
12. Tokmak F, Quack I, Schieren G, et al. High-dose cholecalciferol to correct vitamin D deficiency in haemodialysis patients. Nephrol Dial Transplant. 2008;23(12):4016-20. http://dx.doi.org/10.1093/ndt/gfn367
13. Tangpricha V, Wasse H. Vitamin D therapy in kidney disease: more vitamin D is necessary. Am J Kidney Dis. 2014;64(5):667-9. http://dx.doi.org/10.1053/j.ajkd.2014.08.004
14. Apaydin M, Can AG, Kizilgul M, et al. The effects of single high-dose or daily low-dosage oral colecalciferol treatment on vitamin D levels and muscle strength in postmenopausal women. BMC Endocr Disord. 2018;18(1). http://dx.doi.org/10.1186/
s12902-018-0277-8
15. Jean G, Souberbielle J-C, Chazot C. Monthly cholecalciferol administration in haemodialysis patients: a simple and efficient strategy for vitamin D supplementation. Nephrol Dial Transplant. 2009;24(12):3799-805. http://dx.doi.org/10.1093/ndt/
gfp370
16. Alvarez JA, Law J, Coakley KE, et al. High-dose cholecalciferol reduces parathyroid hormone in patients with early chronic kidney disease: a pilot, randomized, double-blind, placebo-controlled trial. Am J Clin Nutr. 2012;96(3):672-9. http://dx.doi.
org/10.3945/ajcn.112.040642 
17. Ennis JL, Worcester EM, Coe FL, et al. Current recommended 25-hydroxyvitamin D targets for chronic kidney disease management may be too low. J Nephrol. 2016;29(1):63-70. http://dx.doi.org/10.1007/s40620-015-0186-
18. Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr. 1999;69(5):842-56. http://dx.doi.org/10.1093/ajcn/69.5.84
19. Alvarez J, Wasse H, Tangpricha V. Vitamin D supplementation in pre-dialysis chronic kidney disease: A systematic review: A systematic review. Dermatoendocrinol. 2012;4(2):118-27. http://dx.doi.org/10.4161/derm.20014
20. Manson JE, Brannon PM, Rosen CJ, et al. Vitamin D deficiency - is there really a pandemic? N Engl J Med. 2016;375(19):1817-20. http://dx.doi.org/10.1056/NEJMp1608005
21. Friedl C, Zitt E. Vitamin D prohormone in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease. Int J Nephrol Renovasc Dis. 2017;10:109-22. http://dx.doi.org/10.2147/IJNRD.S97637
22. Strugnell SA, Sprague SM, Ashfaq A, et al. Rationale for raising current clinical practice guideline target for serum 25-hydroxyvitamin D in chronic kidney disease. Am J Nephrol. 2019;49(4):284-93. http://dx.doi.org/10.1159/000499187
23. Zehnder D, Bland R, Chana RS, et al. Synthesis of 1,25-dihydroxyvitamin D(3) by human endothelial cells is regulated by inflammatory cytokines: a novel autocrine determinant of vascular cell adhesion. J Am Soc Nephrol. 2002;13(3):621-9. http://
dx.doi.org/10.1681/ASN.V133621
24. Nigwekar SU, Bhan I, Thadhani R. Ergocalciferol and cholecalciferol in CKD. Am J Kidney Dis. 2012;60(1):139-56. http://dx.doi. org/10.1053/j.ajkd.2011.12.035
25. Somjen D, Weisman Y, Kohen F, et al. 25-hydroxyvitamin D3-1alpha-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. Circulation. 2005;111(13):1666-71. http://dx.doi.
org/10.1161/01.CIR.0000160353.27927.70
26. Dusso A, Lopez-Hilker S, Rapp N, et al. Extra-renal production of calcitriol in chronic renal failure. Kidney Int. 1988;34(3):368- 75. http://dx.doi.org/10.1038/ki.1988.190
27. Segersten U, Correa P, Hewison M, et al. 25-hydroxyvitamin D(3)-1alpha-hydroxylase expression in normal and pathological parathyroid glands. J Clin Endocrinol Metab. 2002;87(6):2967-72. http://dx.doi.org/10.1210/jcem.87.6.8604
28. Pike JW, Meyer MB. Regulation of mouse Cyp24a1 expression via promoter-proximal and downstream-distal enhancers highlights new concepts of 1,25-dihydroxyvitamin D(3) action. Arch Biochem Biophys. 2012;523(1):2-8. http://dx.doi.
org/10.1016/j.abb.2011.12.003
29. Kalantar-Zadeh K, Kovesdy CP. Clinical outcomes with active versus nutritional vitamin D compounds in chronic kidney disease. Clin J Am Soc Nephrol. 2009;4(9):1529-39. http://dx.doi.org/10.2215/CJN.02140309
30. Cupisti A, Vigo V, Baronti ME, et al. Vitamin D status and cholecalciferol supplementation in chronic kidney disease patients: An Italian cohort report. Int J Nephrol Renovasc Dis. 2015;8:151-7. http://dx.doi.org/10.2147/IJNRD.S90968
31. Harkness L, Cromer B. Low levels of 25-hydroxy vitamin D are associated with elevated parathyroid hormone in healthy adolescent females. Osteoporos Int. 2005;16(1):109-13. http://dx.doi.org/10.1007/s00198-004-1656-8
32. Massart A, Debelle FD, Racapé J, et al. Biochemical parameters after cholecalciferol repletion in hemodialysis: results from the VitaDial randomized trial. Am J Kidney Dis. 2014;64(5):696-705. http://dx.doi.org/10.1053/j.ajkd.2014.04.020

Most read articles by the same author(s)